TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A mouse study led by University of Barcelona researchers found that tirzepatide — sold as Zepbound and Mounjaro — activated brown adipose tissue, a calorie-burning form of fat, independently of reduced food intake. The findings are not yet confirmed in humans and the researchers caution against assuming the results transfer to people.
A study in mice suggests that tirzepatide — the drug sold as Zepbound and Mounjaro — may improve metabolism directly by activating brown adipose tissue, a form of fat that specializes in burning calories. The research, led by Marion Peyrou of the University of Barcelona, found the drug activated brown fat even when food intake was held constant, indicating effects beyond appetite suppression. The findings have not yet been confirmed in humans.
Tirzepatide is approved for weight management in adults with obesity or overweight with comorbidities, and for treating poorly controlled type 2 diabetes. Unlike some other obesity medications, it targets receptors for two hormonal factors at once — GIP and GLP-1. This dual mechanism produces substantial weight loss, largely by reducing food intake. The research team wanted to determine whether the drug also produces metabolic changes that cannot be explained simply by eating less.
To test this, the researchers examined how tirzepatide affected different fat deposits in obese mice fed a high-fat diet. Treated mice were compared with mice that did not receive the drug but were given the same amount of food, allowing the scientists to separate the drug’s direct effects from those of reduced calorie consumption. According to the study, the analysis showed that tirzepatide activated brown adipose tissue. Unlike white fat, which stores energy and accumulates in obesity, brown fat burns glucose and fat to produce heat.
“This activation is associated with an increased capacity to burn metabolic energy and with the production of batokines by brown adipose tissue, molecules that are beneficial for metabolism,” Peyrou said. The researchers said this could help explain the drug’s positive effects on blood glucose and fat levels in addition to weight reduction. The work was carried out at the Faculty of Biology and the Institute of Biomedicine of the University of Barcelona (IBUB), the Sant Joan de Déu Research Institute (IRSJD) and the CIBER in Physiopathology of Obesity and Nutrition (CIBEROBN).
Why Brown Fat Activation Matters for Obesity Drugs
Scientists have long viewed brown fat activation as a potential strategy for treating obesity and metabolic disease, but earlier drug efforts often failed because of unwanted side effects, particularly on the heart. According to Peyrou, tirzepatide is different: “Tirzepatide, although it activates brown adipose tissue, does not have these negative effects; on the contrary, it shows cardiovascular benefits.”
The results support the idea that obesity therapies may work better when they target several physiological processes at once — reducing appetite and increasing energy expenditure — rather than focusing only on food intake. If confirmed in humans, the researchers said the findings could guide development of broader treatments for obesity, type 2 diabetes and other metabolic disorders, and could help identify which patients — for example those with more compromised energy expenditure — would benefit most from particular drugs.
Tirzepatide and the GLP-1 Drug Class
Tirzepatide is part of the wider wave of GLP-1-based medications that have reshaped obesity and diabetes treatment in recent years. Its dual action on GIP and GLP-1 receptors distinguishes it from single-target drugs in the same class. Clinical use has shown substantial weight loss, but the precise mechanisms by which the drug affects metabolism are still being mapped. This study addresses that gap by using a controlled mouse model, since detailed fat-tissue analysis of this kind cannot readily be performed in humans.
“If our findings are confirmed in humans, it would reinforce the importance of developing therapeutic strategies that not only reduce food intake but also increase energy expenditure and brown fat activation.”
— Marion Peyrou
From Mice to Humans: The Translation Gap
The central uncertainty is whether the brown fat activation observed in mice occurs in the same way in people. The researchers explicitly caution that human and mouse metabolism can differ substantially, as can the distribution of fat tissue and responses to medications. The study has not been validated in human clinical trials, and no claims about brown fat activation should be treated as established effects of Zepbound or Mounjaro in patients at this stage. It is also not yet clear which patient profiles, if any, would show a stronger brown fat response.
Clinical Evidence and Personalized Prescribing Ahead
The researchers say more clinical evidence on how these drugs act on fat in humans is needed. If the mouse findings are confirmed, Peyrou said the work could support more personalized prescribing based on patients’ overall metabolic status — including energy expenditure — rather than appetite or weight alone, and could inform the design of future obesity therapies that combine reduced food intake with increased energy expenditure.
Key Questions
Does Zepbound or Mounjaro definitely burn brown fat in people?
No. The finding comes from a study in mice. The researchers state that more clinical evidence is needed before assuming the same effect occurs in humans.
What is brown adipose tissue?
Brown fat is a specialized form of fat that uses energy and burns calories from glucose and fat, unlike white fat, which primarily stores energy and accumulates in obesity.
How did the researchers separate the drug’s effects from eating less?
They compared tirzepatide-treated mice with untreated mice given the same amount of food, so any differences in fat tissue reflected the drug itself rather than reduced calorie intake.
Could this change how obesity drugs are developed?
Possibly, if confirmed in humans. The researchers argue it would support therapies that both reduce food intake and increase energy expenditure, and could help tailor prescriptions to patients’ metabolic profiles.
Why does brown fat activation usually fail as a drug target?
According to the study, earlier attempts to activate brown fat with drugs often caused unwanted side effects, especially affecting the heart. The researchers note tirzepatide does not show these negative effects in their model.
Source: rss
Columbus Day / Indigenous Peoples' Day Picks
long weekend sales
As an affiliate, we earn on qualifying purchases.
